CARE-ID Joins the Fight Against One of the Top Ten Causes of Death in Older Adults
Annandale, VA; July 21, 2023
The leaders and researchers at the Clinical Alliance for Research and Education-Infectious Diseases (CARE-ID) are pleased to address our first clinical trial collaboration with Johnson and Johnson. The Janssen Pharmaceutical Companies of Johnson & Johnson is a global leader in medicines development, and it is taking a major step in fighting a very serious infectious disease, Invasive Extraintestinal Pathogenic Escherichia Coli (ExPEC) Disease (IED).
Mention of E. coli (Escherichia coli) often brings to mind foodborne illnesses. Most types of E. coli are harmless or cause relatively brief diarrhea. A few particular types can cause more severe stomach cramps, serious diarrhea and vomiting. But there is an even more serious type of E. coli that concerns infectious diseases specialist.
“Bacteremia and sepsis caused by ExPEC bacteria are among the top 10 causes of death in older adults, and the number of cases is rising as the population ages,” says Jan Poolman, Ph.D., Head of Bacterial Vaccines Discovery and Early Development and Disease Area Stronghold Leader Bacterial Vaccines at the Janssen Pharmaceutical Companies of Johnson & Johnson. “At Janssen, we want to help people live longer, healthier lives and enjoy their grandchildren for years to come. Our fight to tackle and limit the burden of ExPEC is one of the ways we hope to realize this vision.”
ExPEC disease is defined as an acute illness consistent with an invasive bacterial infection. The disease is confirmed by the identification of E. coli from blood, or from urine in a patient with urosepsis and no other identifiable source of infection.